Skip to main content

Table 3 Treatment-related adverse events occurring in 10% or more of patients

From: A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Adverse event No. of patients (N = 41)
All grades Grade ≥ 3
Hypertension 27 (66%) 16 (39%)
Fatigue 22 (54%) 4 (10%)
Diarrhea 22 (54%) 1 (2%)
Nausea 20 (49%) 0 (0%)
Constipation 10 (24%) 0 (0%)
Headaches 10 (24%) 0 (0%)
Vomiting 9 (22%) 1 (2%)
Mucositis 6 (15%) 0 (0%)
Proteinuria 6 (15%) 3 (7%)
Dysgeusia 5 (12%) 0 (0%)
GERD 5 (12%) 0 (0%)
Anorexia 4 (10%) 0 (0%)
  1. GERD Gastroesophageal reflux disease